an orally bioavailable radioconjugate composed of pamiparib, a nuclear enzyme poly(adp ribose) polymerase (parp) inhibitor, radiolabeled with the radioisotope carbon c 14, with potential use for evaluating the pharmacokinetic profile of pamiparib. Pamiparib targets, binds to and inhibits parp, which results in the inhibition of tumor cell proliferation and survival. Labeling of pamiparib with the radioactive tracer carbon c 14 allows for the evaluation of pamiparib's pharmacokinetic profile, including its absorption, distribution, metabolism and excretion (adme).
Up to date info
Latest research - 14c pamiparib
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on 14c pamiparib for any updates.